An interventional study of EXOPULSE Mollii Suit + Exercise and EXOPULSE Mollii Suit in Multiple Sclerosis, sponsored by Hacettepe University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Hacettepe University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Multiple Sclerosis by Hacettepe University — 6 open to participants now, 6 under way, none of them phase 3. Multiple Sclerosis · Hacettepe University.
Among the 23 studies in Multiple Sclerosis by Hacettepe University, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 15 with no phase, and was the 18th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →6 of the 23 studies in Multiple Sclerosis by Hacettepe University are open now, in 1 country. Recruiting first, the newest first:
Hacettepe University · Sites in Turkey
Ages 18–65
Hacettepe University · Sites in Turkey
Ages 18+
Hacettepe University · Sites in Turkey
Ages 10+ · Healthy volunteers
Hacettepe University · Sites in Turkey
Ages 18–70
Hacettepe University · Sites in Turkey
Ages 18+
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2025.
This study's enrollment of 31 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 34 across the 15 interventional studies, 56 across the 8 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hacettepe University is the lead sponsor of 1,009 studies on the registry; 214 are open to participants now.
4 of the studies in Multiple Sclerosis by Hacettepe University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137624Hacettepe UniversityMotor Imagery and Action Observation for Gait Function in MS | 2026-11 |
| NCT07151534Hacettepe UniversityBody Awareness, Trunk Stability, and Arm Function in MS | 2026-12-31 |
| NCT07786987Hacettepe UniversityCone Evasion Walk Test in Multiple Sclerosis | 2027-06-30 |
| NCT07899411Hacettepe UniversityEvaluation of the Effect of Mental Imagery Training Combined With Modified Constraint-Induced Movement Therapy in Individuals With Multiple Sclerosis | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 23 studies in Multiple Sclerosis by Hacettepe University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Spasticity affects >80% of MS patients, with 35-54% experiencing moderate-to-severe symptoms, impairing mobility and sleep. Electrical stimulation parameters (e.g., high vs. low frequency) for spasticity management remain debated. The EXOPULSE Mollii Suit uses non-invasive, low-frequency stimulation to induce reciprocal inhibition and modulate spinal interneuron activity, potentially reducing spasticity. This study aims to compare EXOPULSE Mollii + exercise vs. EXOPULSE Mollii alone in improving spasticity and function in MS.
Spasticity is one of the most common symptoms in multiple sclerosis (MS) patients. Large-scale surveys indicate that over 80% of MS patients experience spasticity during their disease course, with 35-54% reporting moderate to severe spasticity. Spasticity, particularly in the lower extremities, is associated with stiffness, spasms, and pain and negatively affects walking, stair climbing, and sleep. While electrical stimulation is a potential treatment for spasticity, optimal stimulation parameters remain unclear. The most commonly used protocol involves high-frequency stimulation (\~100 Hz), though some studies suggest low-frequency stimulation may also be effective.
The EXOPULSE Mollii suit (EXONEURAL NETWORK AB, Danderyd, Sweden) is a non-invasive, self-administered electrical stimulation system with integrated electrodes. It is designed to reduce spasticity and improve motor function in neurological disorders. The method is based on reciprocal inhibition, where low-frequency, low-intensity stimulation of antagonist muscles activates Ia inhibitory interneurons, reducing spasticity in agonist muscles. Additional mechanisms may include neuroplastic changes in spinal or brain circuits, similar to transcutaneous electrical nerve stimulation (TENS). This study aims to compare the effects of EXOPULSE Mollii + exercise vs. EXOPULSE Mollii alone on spasticity and functionality in MS patients.
The criteria were revised on the registry on Nov 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the 60-minute EXOPULSE Mollii stimulation session, patients will also perform a guided exercise program.
Device: EXOPULSE Mollii Suit + Exercise
For 60 minutes, patients will only receive stimulation while wearing the EXOPULSE Mollii suit.
Device: EXOPULSE Mollii Suit
First, spasticity will be evaluated using the Modified Ashworth Scale (MAS). Based on this evaluation, the stimulation intensity for each muscle group will be determined and recorded in the system. Once patients put on the EXOPULSE Mollii Suit and the stimulation begins, they will undergo a personalized exercise program including strengthening, balance, and gait training with scheduled rest intervals. All MS patients will undergo treatment three days per week (with at least one day between sessions) for one hour per day over four weeks.
First, spasticity will be evaluated using the Modified Ashworth Scale (MAS). Based on this evaluation, the stimulation intensity for each muscle group will be determined and recorded in the system. Patients will wear the suit and receive stimulation while resting for 60 minutes. All MS patients will undergo treatment three days per week (with at least one day between sessions) for one hour per day over four weeks.
Modified Ashworth Scale (MAS)
Spasticity in patients will be assessed using the Modified Ashworth Scale (MAS). It grades spasticity based on the resistance exhibited by the muscle, using a scale of 0, 1, 1+, 2, 3, and 4.
Time frame: 4 weeks
Berg Balance Scale (BBS)
This 14-item scale is scored from 0 to 4 for each item. A score of 0 indicates inability to perform, while a score of 4 indicates normal performance. With a maximum total score of 56, higher scores indicate better balance ability.
Time frame: 4 weeks
OptoGait Gait Analysis System
During the test, the patient is asked to step onto the treadmill. They are then asked to adjust the treadmill speed to their preferred pace and walk for one minute. While walking on the treadmill, objective data related to their gait's time-distance characteristics is obtained. The evaluation takes five minutes.
Time frame: 4 weeks
EDSS (Expanded Disability Status Scale)
The severity of the disease will be assessed using the Expanded Disability Status Scale (EDSS). This assessment is based on a clinician's interview and the patient's neurological status. A score of 0 represents normal neurological status, while a score of 10 indicates worsening MS. The next score after 0 is 1, and clinical deterioration is expressed in 0.5-point increments thereafter. The EDSS score is calculated using a rating scale of 0.0 to 4.0 for pyramidal, cerebellar, brainstem, sensory, visual, bowel-bladder, and mental functions. The rating is based on the patient's best performance without excessive effort. A score of 0-4 indicates independence; 6.0, unilateral support; 6.5, bilateral support; and 7.0 or higher, dependence.
Time frame: 4 weeks
Visual Analog Scale (VAS) for pain and fatigue
The Visual Analog Scale will be used to assess pain and fatigue. Patients will rate their pain and fatigue on a 10-cm line. "No pain-no fatigue" will be scored as 0 points, and "the worst pain imaginable-the worst fatigue" will be scored as 10 points.
Time frame: 4 weeks
Fatigue Severity Scale
The Fatigue Severity Scale (FSS) is a nine-item scale that measures the severity of fatigue and its impact on patients' activities and lifestyle. Each item is scored on a scale from 1 to 7. A score of 1 indicates strong disagreement with the statement, while a score of 7 indicates strong agreement. The lowest possible total score is 7, and the highest possible total score is 63. The higher the score, the greater the fatigue severity.
Time frame: 4 weeks
9-Hole Peg Test
A nine-hole peg test will be used to evaluate hand function. The time it takes individuals to insert and remove the nine pegs from the holes will be recorded. Participants will perform the test with both their dominant and non-dominant hands.
Time frame: 4 weeks
5 Times Sit to Stand Test
Functional strength of the lower extremities will be assessed using the Five Times Sit-to-Stand Test. For this test, a standard-sized chair with a backrest (43-45 cm) is used. The patient sits on the chair with their back against the backrest. Each repetition of sitting down and standing up is counted. The time it takes to complete five repetitions is recorded using a stopwatch.
Time frame: 4 weeks
Timed Up and Go (TUG) Test
The TUG test measures functional mobility skills and risk of falling. For this test, participants stand up from a chair, walk three meters, turn around, walk back, and sit down again. The time it takes to complete this task is used to determine functional mobility. Completing the task in ≤10 seconds indicates normal functional mobility. Completing it in \<20 seconds indicates good mobility, meaning the individual can walk without assistive devices and go out alone. Completing it in \<30 seconds indicates a mobility issue, meaning the individual needs to use assistive devices and cannot go out alone.
Time frame: 4 weeks
10 meter Walk Test
A 10-meter walking test will be performed to evaluate patients' walking ability. Participants will walk 10 meters, and their time will be recorded with a stopwatch. The average time will be calculated based on three repetitions. Walking speed (m/s) will be calculated by dividing the walking distance (10 meters) by the average time obtained. Walking speeds are categorized as follows: \<0.4 m/s indicates ambulation within the home, 0.4-0.8 m/s indicates limited ambulation outside the home, and \>0.8 m/s indicates ambulation outside the home.
Time frame: 4 weeks
12-Item Multiple Sclerosis Walking Scale
It assesses the patient's walking abilities over the past two weeks from their perspective. Each question is scored on a five-point scale. Patients are asked to rate themselves as follows: 1 = none; 2 = slight; 3 = moderate; 4 = severe; and 5 = very severe. A high score indicates difficulty walking.
Time frame: 4 weeks
Functional Independence Measure (FIM)
Activities daily living will be assessed using the Functional Independence Measure (FIM). The FIM consists of 18 items that cover self-care, sphincter control, mobility, movement, communication, and social interaction. Scores range from 18 to 126.
Time frame: 4 weeks
Multiple Sclerosis Quality of Life-54 (MSQOL-54)
It is a measure created by adding 18 multiple sclerosis (MS)-specific items to the Short Form 36 (SF-36), which contains 36 questions related to overall quality of life. Patients receive two separate scores, one for physical health and one for mental health. Higher scores indicate better outcomes. The scale's subparameters include physical health, physical role limitations, emotional role limitations, pain, energy levels, perceived health, social functions, cognitive functions, sexual functions, and overall quality of life. Total mental and physical scores are calculated based on the different coefficients of each sub-parameter.
Time frame: 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Jun 2026, 9 months.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 9 months is below that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jan 2026 → Jun 2026 and completion Feb 2026 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.